Phase I bridging study of ch14.18/CHO long-term infusion in recurrent or refractory neuroblastoma patients in Japan.

Yoshiyuki Takahashi,Atsushi Narita,Nikolai Siebert,Nobuhiro Nishio,Yinyan Xu,Hideki Muramatsu,Asahito Hama,Takehiko Kamijo,Atsuko Nakazawa,Hajime Hosoi,Yoshiaki Kinoshita,Shinobu Shimizu,Katsuyoshi Kato,Masaaki Mizuno,Hans Loibner,Tatsuro Tajiri,Akira Nakagawara,Ruth Ladenstein,Holger N. Lode,Seiji Kojima

Phase I bridging study of ch14.18/CHO long-term infusion in recurrent or refractory neuroblastoma patients in Japan.

2016

10568Background: The primary objective of this study was to assess safety and toxicity of anti-GD2 antibody ch14.18/CHO continuous long term infusion (LTI) used as single agent in Japanese pediatri...

Keywords:

Neuroblastoma
Bridging (networking)
Physical therapy
Internal medicine
Cardiology
Medicine
Antibody
Oncology
Refractory
Toxicity
single agent
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations